MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.07
-0.20
-1.23%
Closed 16:04 03/27 EDT
OPEN
15.86
PREV CLOSE
16.27
HIGH
16.51
LOW
15.67
VOLUME
382.79K
TURNOVER
--
52 WEEK HIGH
39.15
52 WEEK LOW
13.12
MARKET CAP
844.22M
P/E (TTM)
7.63
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SUPN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SUPN stock price target is 25.67 with a high estimate of 32.00 and a low estimate of 20.00.

EPS

SUPN News

More
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Need To Know: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Have Been Buying Shares
  • Simply Wall St. · 03/16 15:34
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • Edited Transcript of SUPN earnings conference call or presentation 26-Feb-20 2:00pm GMT
  • Thomson Reuters StreetEvents · 03/12 07:54

Industry

Pharmaceuticals
-0.41%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SUPN

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
More

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.